| 查看: 1377 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
药学专硕调剂
已经有0人回复
-
publcif的使用
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有169人回复
-
求调剂
已经有2人回复
-
会计专硕求调剂
已经有0人回复
-
新加坡国立大学药学系化学生物学课题组招PhD
已经有14人回复
-
请教酰胺缩合反应
已经有4人回复
-
一志愿大连理工制药工程专硕086002，本科211，总分342
已经有0人回复
-
制药工程专业招收调剂，要求过国家线
已经有0人回复
-
五邑大学药物化学生物学团队-李兰清课题组招收调剂学生
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
三峡大学生态学招硕士调剂
+2/186
-
南宁师范大学贺益苗课题组2026年招收有机化学和材料与化工专业拟招生4-5名硕士研究生
+1/184
-
马尔文激光粒度+纳米粒径Zeta电位测试原始数据与Origin绘图V131/2039/8821
+1/91
-
招聘︱国家纳米科学中心丁宝全杰青团队诚聘博士后（特别研究助理）
+2/48
-
浙江省人民医院博士后岗位招聘
+1/33
-
双一流大学湘潭大学“化工过程模拟与强化”国家地方联合工程研究中心招收各类博士生
+1/16
-
【实战型】【生物医药】2026青岛大学招博士生 含少数民族骨干计划2名！
+1/14
-
中南大学喻桂朋教授团队新增2026年博士研究生
+1/11
-
港科大（广州）招收光学传感器，集成电路设计，医学影像设备以及可穿戴设备方向的博士
+1/9
-
西安工程大学环境与化学工程学院能源环境催化与先进材料课题组招生
+1/9
-
中国科学院上海硅酸盐研究所招聘科研助理（纳米材料与生物应用方向）
+1/7
-
宁夏大学化学化工学院魏逸彬研究员课题组招聘启事
+1/7
-
国家双一流高校-国家级青年人才课题组博士招生
+1/7
-
【水文、水质模拟】香港科技大学（广州）博士后招聘
+1/6
-
昆工 轻工 招收调剂
+1/5
-
武汉理工大学船海与能源动力工程学院 刘鹏飞院士团队专任教师招聘启事
+1/5
-
武汉纺织大学沈爱国教授团队招收化学、生物、材料专业研究生
+1/5
-
中国科学技术大学纳米科学技术学院张振教授/江雷院士诚招2026级博士
+1/3
-
26年环境博士申请
+1/3
-
教育部重点实验室招收2026年调剂生，化学、材料、机械、计算机等
+1/1
10楼2015-09-01 08:19:15
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
11楼2015-09-14 11:50:36
